A modified TALEN-based system for robust generation of knock-out human pluripotent stem cell lines and disease models

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Frank, Stefan ^a,b   Skryabin, Boris V ^c   Greber, Boris ^a,b  

^a CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Disease modeling; Human pluripotent stem cells; TALE nucleases; Targeted gene disruption

Indexed keywords

NUCLEASE; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE MODEL; EXPRESSION VECTOR; FEMALE; GENE; GENE DISRUPTION; GENE INACTIVATION; GENE TARGETING; HPRT1 GENE; HUMAN; HUMAN CELL; LESCH NYHAN SYNDROME; NERVE CELL DIFFERENTIATION; PLURIPOTENT STEM CELL;

DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; ENDONUCLEASES; FEMALE; GENE KNOCKOUT TECHNIQUES; GENE TARGETING; GENOMICS; HOMOZYGOTE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LESCH-NYHAN SYNDROME; PLURIPOTENT STEM CELLS; RECOMBINANT FUSION PROTEINS; SENSORY RECEPTOR CELLS; TRANS-ACTIVATORS;

EID: 84887030890     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-773     Document Type: Article

References (30)

1. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011, 29:731-734. 10.1038/nbt.1927, 3152587, 21738127.
2. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326:1509-1512. 10.1126/science.1178811, 19933107.
3. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science 2009, 326:1501. 10.1126/science.1178817, 19933106.
4. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, Bogdanove AJ, Voytas DF. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010, 186:757-761. 10.1534/genetics.110.120717, 2942870, 20660643.
5. Streubel J, Blucher C, Landgraf A, Boch J. TAL effector RVD specificities and efficiencies. Nat Biotechnol 2012, 30:593-595. 10.1038/nbt.2304, 22781676.
6. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011, 29:143-148. 10.1038/nbt.1755, 21179091.
7. Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, Kuperwasser N, Motola DL, Meissner TB, Hendriks WT, et al. A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models. Cell Stem Cell 2012, 12:238-251.
8. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012, 30:460-465. 10.1038/nbt.2170, 3558947, 22484455.
9. Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G, Zhang F. A transcription activator-like effector toolbox for genome engineering. Nat Protoc 2012, 7:171-192. 10.1038/nprot.2011.431, 3684555, 22222791.
10. Schmid-Burgk JL, Schmidt T, Kaiser V, Honing K, Hornung V. A ligation-independent cloning technique for high-throughput assembly of transcription activator-like effector genes. Nat Biotechnol 2012, 31:76-81.
11. Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011, 29:149-153. 10.1038/nbt.1775, 3084533, 21248753.
12. Sakuma T, Hosoi S, Woltjen K, Suzuki KI, Kashiwagi K, Wada H, Ochiai H, Miyamoto T, Kawai N, Sasakura Y, et al. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells 2013, 18:315-326. 10.1111/gtc.12037, 23388034.
13. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011, 39:e82. 10.1093/nar/gkr218, 3130291, 21493687.
14. Visser JE, Bar PR, Jinnah HA. Lesch-Nyhan disease and the basal ganglia. Brain Res Brain Res Rev 2000, 32:449-475. 10.1016/S0165-0173(99)00094-6, 10760551.
15. Jinnah HA. Lesch-Nyhan disease: from mechanism to model and back again. Dis Model Mech 2009, 2:116-121. 10.1242/dmm.002543, 2650214, 19259384.
16. Xu C, Inokuma MS, Denham J, Golds K, Kundu P, Gold JD, Carpenter MK. Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol 2001, 19:971-974. 10.1038/nbt1001-971, 11581665.
17. Frank S, Zhang M, Schöler HR, Greber B. Small molecule-assisted, line-independent maintenance of human pluripotent stem cells in defined conditions. PLoS One 2012, 7:e41958. 10.1371/journal.pone.0041958, 3408405, 22860038.
18. Mekhoubad S, Bock C, de Boer AS, Kiskinis E, Meissner A, Eggan K. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 2012, 10:595-609. 10.1016/j.stem.2012.02.014, 3603710, 22560080.
19. Greber B, Coulon P, Zhang M, Moritz S, Frank S, Muller-Molina AJ, Arauzo-Bravo MJ, Han DW, Pape HC, Scholer HR. FGF signalling inhibits neural induction in human embryonic stem cells. EMBO J 2011, 30:4874-4884. 10.1038/emboj.2011.407, 3243624, 22085933.
20. Guo J, Gaj T, Barbas CF. Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol 2010, 400:96-107. 10.1016/j.jmb.2010.04.060, 2885538, 20447404.
21. Sander JD, Cade L, Khayter C, Reyon D, Peterson RT, Joung JK, Yeh JR. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol 2011, 29:697-698. 10.1038/nbt.1934, 3154023, 21822241.
22. Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 2013, 12:393-394. 10.1016/j.stem.2013.03.006, 23561441.
23. Meek S, Buehr M, Sutherland L, Thomson A, Mullins JJ, Smith AJ, Burdon T. Efficient gene targeting by homologous recombination in rat embryonic stem cells. PLoS One 2010, 5:e14225. 10.1371/journal.pone.0014225, 2997056, 21151976.
24. Haurwitz RE, Jinek M, Wiedenheft B, Zhou K, Doudna JA. Sequence- and structure-specific RNA processing by a CRISPR endonuclease. Science 2010, 329:1355-1358. 10.1126/science.1192272, 3133607, 20829488.
25. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013, 31:227-229. 10.1038/nbt.2501, 3686313, 23360964.
26. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013, 31:233-239. 10.1038/nbt.2508, 3748948, 23360965.
27. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife 2013, 2:e00471. 3557905, 23386978.
28. Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013, 31:230-232. 10.1038/nbt.2507, 23360966.
29. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823. 10.1126/science.1231143, 3795411, 23287718.
30. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826. 10.1126/science.1232033, 3712628, 23287722.